They are tea leaves at this point, but we know the goal. The truth is that there are likely a few different rational courses of action one might take to meet that goal, but we are not Captains of this ship, so deliberating on what lies behind the veil is fraught with rational guesses.
I'd venture to say that if we were truly on the inside, we'd agree with 90% of the decisions made. We'd see the predatory attacks on this company's existence, we'd understand the power of the immune system but also the patience required to obtain data results that reflect well understood observations.
We'd understand the economics and timing related to manufacturing, trial completion and clinic/caregiver readiness, and we'd comprehend why NWBO utilizes trial infrastructure to create Centers of Excellence. We'd appreciate why Compassionate Use and Hospital Exemption programs can pave the way to reimbursement for a new therapeutic paradigm
I personally don't think NWBO is simply in hunker down mode. I speculate they also anticipate their own counter attack. There is simply no way in the past any efforts in that vain could break the organized defense of NWBO's critiques, because NWBO simply wasn't far enough along to do it.
When will they be? It all depends on results. Immunotherapeutic cancer Vaccines litter the seas with once mighty ships reduced by the double blinded trial. Only one DC immunotherapeutic cancer vaccine actually gained passage to commercialization, but it was version 1.0, and ill equipped to handle the onslaught it received from large global forces. NWBO has no intention to repeat Dendreon's prior course. If NWBO is able to navigate safely and significantly through pivotal trials, it must then execute a successful commercial launch.
News 
Market Data 
Discover 
